Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization [Yahoo! Finance]
PLUS THERAPEUTICS, Inc. (PSTV)
Company Research
Source: Yahoo! Finance
HOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today provides a business update and highlights REYOBIQ clinical progress and CNSide US commercialization. “Our 2 key goals in 2026 are CNSide commercial scale-up and REYOBIQ pivotal trial readiness,” said Dr. Marc H. Hedrick, President & Chief Executive of Plus Therapeutics. “Our recently completed upsized $15 million offering will fuel faster progress in these core areas of the business and extend our cash runway through 2027.” Overview of anticipated company milestones for 2026: REYOBIQ clinical program: Define optimal dose/interval for REYOBIQ in the ReSPECT-LM Phase 2 trial; anticipate reporting data in Q3 2026 Completing enrollment in the ReSPECT-GBM Phase 2 trial for glioblastoma and conduct an end of phase meeting with the FDA to
Show less
Read more
Impact Snapshot
Event Time:
PSTV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PSTV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PSTV alerts
High impacting PLUS THERAPEUTICS, Inc. news events
Weekly update
A roundup of the hottest topics
PSTV
News
- How Analyst Revisions Are Rewriting The Story For Plus Therapeutics (PSTV) [Yahoo! Finance]Yahoo! Finance
- Plus Therapeutics (NASDAQ:PSTV) is now covered by analysts at Lake Street Capital. They set a "buy" rating and a $2.00 price target on the stock.MarketBeat
- Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Plus Therapeutics, Inc. (PSTV) Discusses Business Update, REYOBIQ Clinical Program Progress, and Recent Financial Offering Transcript [Seeking Alpha]Seeking Alpha
- Plus Therapeutics (NASDAQ:PSTV) had its price target lowered by analysts at D. Boral Capital from $5.00 to $4.00. They now have a "buy" rating on the stock.MarketBeat
PSTV
Earnings
- 8/14/25 - Beat
PSTV
Sec Filings
- 1/22/26 - Form SCHEDULE
- 1/22/26 - Form 8-K
- 1/16/26 - Form 8-K
- PSTV's page on the SEC website